Four serum neurofilament light chain tests show high accuracy in diagnosing ALS and predicting its progression, new research suggests.
Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback